FDA.reportPublic FDA data

selpercatinib 40 MG Oral Capsule [Retevmo]

RxCUI
2370170
RxNorm name
selpercatinib 40 MG Oral Capsule [Retevmo]
Display name
selpercatinib 40 MG Oral Capsule [Retevmo]
Full name
selpercatinib 40 MG Oral Capsule [Retevmo]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:05

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
7fa848ba-a59c-4144-9f52-64d090f4d828Retevmo 40 MG Oral Capsule [PSN] · selpercatinib 40 MG Oral Capsule [Retevmo] [SBD] · Retevmo 40 MG Oral Capsule [SY]322These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO. RETEVMO ® (selpercatinib) capsules, for oral use RETEVMO ® (selpercatinib) tablets, for oral use Initial U.S. Approval: 202020251120